Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 10, 2012, Pages 1407-1415

  Dudareva Vizule, Sandra ^a   Koch, Judith ^a   Heiden, Matthias Der ^a   Oberle, Doris ^b   Keller Stanislawski, Brigitte ^b   Wichmann, Ole ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Confidence interval; Eastern federal states; EFS; German Standing Committee on Vaccination; Germany; Hospitalization; Impact; Incidence; Incidence rate ratios; Incidence rates; IR; IRR; Nosocomial Abbreviations: CI; Rotavirus; Rotavirus; STIKO; RV; United States; US; Vaccination; Western federal states; WFS

Indexed keywords

EID: 84868271562     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21593     Document Type: Article

References (33)

1. Soriano-Gabarró M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006; 25(Suppl):S7-11; PMID:16397431; http://dx.doi.org/10.1097/01.inf.0000197622. 98559.01.
2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565- 72; PMID:12737740; http://dx.doi.org/10.3201/eid0905.020562.
3. Koch J, Wiese-Posselt M. Epidemiology of rotavirus infections in children less than 5 years of age: Germany, 2001-2008. Pediatr Infect Dis J 2011; 30:112-7; PMID:20724954; http://dx.doi.org/10.1097/INF.0b013e3181f1eb21.
4. Robert Koch -Institut. Infektionsepidemiologisches Jahrbuch für 2010, Berlin, 2011.
5. Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M, Group RS; REVEAL Study Group. Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study. J Infect Dis 2007; 195(Suppl 1):S36-44; PMID:17539193; http://dx.doi.org/10.1086/516716.
6. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, doubleblind controlled study. Lancet 2007; 370:1757-63; PMID:18037080; http://dx.doi.org/10. 1016/S0140-6736(07)61744-9.
7. Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M, et al. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis 2007; 11(Suppl 2):S29-35; PMID:18162243; http://dx.doi.org/10.1016/S1201- 9712(07)60019-8.
8. Linhares AC, Velázquez FR, Pérez-Schael I, Sáez- Llorens X, Abate H, Espinoza F, et al.; Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double- blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9; PMID:18395579; http://dx.doi.org/10.1016/S0140-6736(08)60524- 3.
9. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al.; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/ NEJMoa052434.
10. Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, et al. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 2011; 29:6335- 41; PMID:21640780; http://dx.doi.org/10.1016/j.vaccine.2011.05.017.
11. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27:5936-41; PMID:19679216; http://dx.doi.org/10.1016/j.vaccine.2009.07.098.
12. Böhmer MM, Walter D, Krause G, Müters S, Gösswald A, Wichmann O. Determinants of tetanus and seasonal influenza vaccine uptake in adults living in Germany. Hum Vaccin 2011; 7:1317-25; PMID:22108034; http://dx.doi.org/10.4161/hv.7.12.18130.
13. Siedler A, Mankertz A, Feil F, Ahlemeyer G, Hornig A, Kirchner M, et al. Closer to the goal: efforts in measles elimination in Germany 2010. J Infect Dis 2011; 204(Suppl 1):S373-80; PMID:21666187; http://dx.doi.org/10.1093/infdis/ jir068.
14. Böhmer MM, Walter D, Müters S, Krause G, Wichmann O. Seasonal influenza vaccine uptake in Germany 2007/2008 and 2008/2009: results from a national health update survey. Vaccine 2011; 29:4492- 8; PMID:21545822; http://dx.doi.org/10.1016/j.vaccine.2011.04.039.
15. IMS Pharmascope®. Online available: http://www. imshealth.de 16. Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011; 29:2791-6; PMID:21320539; http:// dx.doi.org/10.1016/j.vaccine.2011.01.104.
16. Itzler R, Koch G, Matson DO, Gothefors L, Van Damme P, Dinubile MJ, et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatr 2010; 10:42; PMID:20540778; http:// dx.doi.org/10.1186/1471-2431-10-42.
17. Tate JE, Panozzo CA, Payne DC, Patel MM, Cortese MM, Fowlkes AL, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465- 71; PMID:19581260; http://dx.doi.org/10.1542/peds.2008-3528.
18. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697-700; PMID:18583958.
19. Centers for Disease Control and Prevention (CDC). Reduction in rotavirus after vaccine introduction- -United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58:1146-9; PMID:19847149.
20. Payne DC, Staat MA, Edwards KM, Szilagyi PG, Weinberg GA, Hall CB, et al.; New Vaccine Surveillance Network (NVSN). Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011; 53:245-53; PMID:21705316; http://dx.doi.org/10. 1093/cid/cir307.
21. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009; 16:382- 6; PMID:19158283; http://dx.doi.org/10.1128/CVI.00382-08.
22. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr Infect Dis J 2010; 29:319- 23; PMID:19935446.
23. Yen C, Tate JE, Wenk JD, Harris JM 2nd, Parashar UD. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011; 127:e9-15; PMID:21172995; http:// dx.doi.org/10.1542/peds.2010-1393.
24. Anderson EJ, Rupp A, Shulman ST, Wang D, Zheng X, Noskin GA. Impact of rotavirus vaccination on hospital-acquired rotavirus gastroenteritis in children. Pediatrics 2011; 127:e264-70; PMID:21262887; http://dx.doi.org/10. 1542/peds.2010-1830.
25. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, et al. Reduction in rotavirusassociated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 2011; 30(Suppl):S25-9; PMID:21183837; http://dx.doi.org/10.1097/INF.0b013e3181fefdee.
26. Clarke MF, Davidson GP, Gold MS, Marshall HS. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalizations in South Australian children following the introduction of rotavirus vaccination. Vaccine 2011; 29:4663-7; PMID:21575665; http://dx.doi.org/10.1016/j.vaccine.2011.04. 109.
27. Atkins KE, Shim E, Pitzer VE, Galvani AP. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012; 30:552-64; PMID:22133508; http://dx.doi.org/10.1016/j.vaccine.2011.11.064.
28. Zeller M, Rahman M, Heylen E, De Coster S, De Vos S, Arijs I, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28:7507-13; PMID:20851085; http://dx.doi.org/10.1016/j.vaccine.2010.09.004.
29. Gagneur A, Nowak E, Lemaitre T, Segura JF, Delaperrière N, Abalea L, et al.; IVANHOE investigators. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the IVANHOE study. Vaccine 2011; 29:3753-9; PMID:21443962; http://dx.doi.org/10.1016/j.vaccine.2011.03.035.
30. Bruijning-Verhagen P, Quach C, Bonten M. Nosocomial rotavirus infections: a meta-analysis. Pediatrics 2012; 129:e1011-9; PMID:22392170; http://dx.doi.org/10.1542/peds.2011-2779.
31. Jahre nach dem Fall der Mauer: Wie hat sich die Gesundheit in Deutschland entwickelt? Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch-Institut, 2009.
32. German Federal Statistical Office. Online available: http://www.destatis. de.
33. Krause G, Altmann D, Faensen D, Porten K, Benzler J, Pfoch T, et al. SurvNet electronic surveillance system for infectious disease outbreaks, Germany. Emerg Infect Dis 2007; 13:1548-55; PMID:18258005; http://dx.doi.org/10. 3201/eid1310.070253.